Analysis of Genentech’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

High impact company profile available at BioMarket

Overview of adjuvants for prophylactic vaccines with detailed profiles and critical assessment of key products. Discussion of the regulatory environment with strategic recommendations for adjuvant developers to optimize chances of market approval.

Iomai Corporation: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

The report "Asia Pacific Biotechnology Market (2007-2010)" provides an updated and detailed overview of the Asia-Pacific Biotechnology industry.

This analysis examines the historical and forecast performance for Biogen Idec in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year

This analysis examines the historical and forecast performance for Watson in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

This report provides an overview of the pharmaceutical distribution model in Europe and the US, and highlights recent changes in the supply chain that impact on the industry, particularly with regards to parallel trade and counterfeit strategies.

This market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition.

A report that provides a detailed examination of the current market for immunomodulatory therapies.

The Bayer Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Pfizer Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

The Solvay Partnering Guide 2008 provides an in-depth insight into the dealmaking interests and activity of one of the worlds leading biopharma companies

Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large pati

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of helminthic infestations drugs by company and by stage as well as a summary of the latest news and developments in this area.

Parkinson’s disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the se

There are today more than 175 therapeutics targeting pancreatic cancer, from early preclinical to marketed drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked

High impact company profile available at BioMarket

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of hypogonadism drugs by company and by stage as well as a summary of the latest news and developments in this area.

The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key br

Orexigen Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

High impact company profile available at BioMarket

Danaher is a diversified technology company engaged in designing, manufacturing and marketing of professional, medical, industrial and consumer products with strong brand names and significant market positions.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of bronchospasm drugs by company and by stage as well as a summary of the latest news and developments in this area.

In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now?

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only

Analysis of Roche’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

Detailed forecast (US, JPN, GER, ITA, ESP, UK) for key marketed and pipeline hospital antibiotics. Discussion of key drivers, threats, and strategic analysis of opportunities in a market beset by generic erosion and similarly targeted new entrants.

This brief offers an analysis of PLM technology and the six key features that will make PLM successful in the pharmaceutical industry.